Catalio Capital Management Raises More than $325M in its Oversubscribed Second Credit Fund to Enable Healthcare Innovation Through Structured Credit

Structured Opportunities platform exceeds targets for its second fund, reinforcing growing demand for alternatives to dilutive equity issuance

NEW YORK–(BUSINESS WIRE)–Catalio Capital Management, LP (“Catalio”), a leading innovative healthcare investment firm, today announced the successful close of its second credit fund, Catalio Structured Opportunities Fund II, exceeding its fundraising target with more than $325 million in commitments across the Fund and its co-investment vehicles.

In an environment where healthcare companies continue to face significant fundraising challenges, companies are increasingly seeking to preserve equity while securing structured capital to preserve growth. Focused on the full lifecycle of innovative healthcare investing across a multi-strategy platform, Catalio launched its Structured Opportunities strategy in late 2021 to address this need and provide companies with an alternative to traditional equity financing.

“We greatly appreciate the commitment of our investors, many of whom have supported our vision from day one,” said John Henry Iucker, Founding Partner and Head of Credit at Catalio. “The Catalio Structured Opportunities Fund provides innovative healthcare companies with flexible capital at a critical stage of their growth and commercial execution. We’re using what Catalio is known for – a multi-strategy platform led by industry experts – to address capital scarcity and bring life changing healthcare innovations to market.”

Catalio’s Structured Opportunities strategy focuses on commercial-stage targets with scientific and clinical expertise, and meaningful revenue growth or cashflow drivers. Investments span across senior secured debt to structured equity, offering creative, tailored finance solutions to support innovation and capital needs at this critical stage of the lifecycle.

To date, the strategy has completed 21 investments, demonstrating continued industry demand for credit-based financing and confidence in Catalio’s differentiated platform.

Recent highlights from the Catalio Structured Opportunities Fund II include:

• Leading Leo Cancer Care’s $40 million funding round with a $20 million credit investment, driving the commercialization of next-generation upright radiotherapy systems. Leo’s proton and photon therapy systems are designed to improve patient comfort and enhance treatment precision, an innovation critical for the treatment of head and neck cancers where patient positioning in traditional systems results in sub-optimal outcomes.
• A $20 million credit investment in Amalgam Rx, Inc. to accelerate the scaling of medical-grade AI solutions, demonstrating Catalio’s continued leadership in the healthcare AI space. Amalgam leads its category in key high-impact innovations, such as FDA-cleared prescription digital therapeutics that pair prescriptions with software to assist patients with dose management and medical adherence.

About Catalio Capital Management, LP:

Catalio Capital Management, LP, is a New York-based investment firm focused on the full lifecycle of innovative healthcare investing across private, public and credit markets. Catalio has exclusive partnerships with world-renowned serial scientist-entrepreneurs from around the globe who each have extensive academic and scientific achievements and who have also started multiple well-established companies based on their research. Catalio has offices in New York, London, and Washington, D.C. Learn more about Catalio Capital Management by visiting www.cataliocapital.com.

Contacts

Media Contact
catalio@rubenstein.com